Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437034 · ClinicalTrials.gov registry record · Phase 2
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00437034: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00437034 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00437034, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment. Aflibercept may be able to carry cancer-killing substances directly to multiple myeloma cells. It may also stop the growth of multiple myeloma by blocking blood flow to the cancer.
Interventions
- BIOLOGICAL aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437034
The ClinicalTrials.gov registry entry for NCT00437034 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aflibercept is the first listed.
NCT00437034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437034 about?
NCT00437034 is a clinical study titled "Aflibercept for Relapsed Multiple Myeloma". This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment. Aflibercept may be able to carry cancer-killing substances directly to multiple myeloma cells. It...
What is the current status of trial NCT00437034?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2007-01. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00437034?
The interventions under investigation include: aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00437034?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.